Day 1 *AGENDA IS SUBJECT TO CHANGE*Monday, 23 March 2026

Location: Room Porto

The biopharma investment landscape is constantly evolving—shaped by scientific breakthroughs, shifting capital flows, and global dynamics. After a period of contraction, where funding tightened and valuations recalibrated, investors and innovators are seeking the next wave of opportunity.

Join this session as experts share an insider's view how leading venture capital firms and strategic investors are positioning themselves for the future. Understand where the market is headed, what types of innovation are attracting the most attention, how both early- and late-stage companies can best align their strategies with investor priorities and how new deal structures, capital efficiency strategies, and ecosystem partnerships are benefitting biotech’s. The discussion will offer practical guidance for companies seeking to secure funding and navigate toward long-term success, in today’s waves of uncertainty.

Location: Room Porto

Explore the art of deal-making through the lens of recent successes, such as...

Location: Room Porto

As the biotech and pharma sectors enter a pivotal year, dealmaking remains the steady anchor amid unpredictable market tides. In this session, analysts and experienced BD executives from pharma and biotech will explore the forces shaping partnering and M&A in 2026, including the financing climate, emerging therapeutic trends, and geopolitical factors influencing cross-border transactions. With early post-JPM signals on the horizon, the discussion will examine how companies can capture momentum, build resilience, and seize the next wave of opportunity. Discover how strategic collaboration and smart capital deployment can guide innovation towards sustainable growth in a shifting global landscape.

Location: Room Sintra

Powered by leading analyst intelligence and data-driven insights, this session offers a comprehensive exploration of the evolving therapeutic landscape. Dive into emerging trends, market dynamics, and investment opportunities across key therapeutic areas, and uncover how shifting R&D pipelines, regulatory changes, scientific breakthroughs, and technological advancements are transforming the biopharma industry. Gain a forward-looking perspective on the most promising therapeutic areas and high-growth investment opportunities, equipping you with the strategic insights needed to navigate 2026 and beyond.

Location: Room Sintra

Oncology continues to be a cornerstone of therapeutic innovation, with significant progress and emerging patterns reshaping the fight against cancer. This session will explore the latest advancements in oncology, from precision medicine and immunotherapies to novel modalities, combination treatments, and the use of alternative data points for pre-clinical development and clinical trial optimization. Experts will discuss the evolving investment landscape, strategies for navigating regulatory pathways, improving patient access, and fostering collaborations to accelerate innovation and create a brighter future for patients.

Location: Room Sintra

Immunology stands as a cornerstone of therapeutic innovation, influencing nearly every major therapeutic area. This panel will delve into next-generation approaches to immune diseases, spotlighting groundbreaking advancements and emerging trends which are paving the way for the development of more effective and targeted therapies. Examine the latest deals and the dynamic momentum of partnerships between pharma, biotech, and academia, highlighting how strategic collaborations are accelerating innovation and overcoming translational challenges to address pressing challenges and have a transformative impact on global health.

Location: Room Sintra

The rare disease space continues to be a frontier of unmet need and innovation. This session will convene leading voices to explore how scientific precision, strategic partnerships, capital, and novel business models are accelerating drug development. Through real-world insights, panelists will explore the critical role of patient-centric approaches in R&D and the use of real-world evidence, while addressing the complexities of clinical development, commercialization, and building sustainable pipelines in the face of regulatory, reimbursement, and patient access challenges. Discover what makes a rare disease company fundable today and the mindsets shaping the future of rare disease innovation and partnerships.

Location: Exhibit Hall Stage

Long before biotech entered the national spotlight, Pedro de Noronha Pissarra transformed scientific ambition into enterprise, playing a pivotal role in shaping Portugal's biotech ecosystem and establishing Portugal’s place on the global biotech map. His journey, spanning from Lisbon’s laboratories to international boardrooms, reflects resilience, creativity, and a born-global mindset that continues to inspire the next generation of innovators. This fireside chat will explore the origins of Portugal’s biotech ecosystem, offer insights into building a life sciences sector in an emerging market, lessons on taking science beyond borders, and the lasting impact of mentorship and leadership in shaping budding innovators.

TREOS Bio is a clinical-stage biotech with a mission to change the paradigm of active cancer immunotherapy development.

- Founded by Hungarian/US/Italian scientists; launched in 2017 as UK company, based in London, Budapest and Boston

- Novel perspective on how HLA genes influence immune responses to cancer

- Coherent immuno-clinical correlation reported from three Phase I/II clinical trials in MSS colorectal cancer conducted in partnership with Mayo Clinic (n=44)

- Proprietary data science platform PEPI Technology: "Promiscuous Epitope"—a small protein fragment binding multiple MHC molecules of a person, thereby triggering exceptionally strong immune responses against tumor antigens — far surpassing the effectiveness of “common” epitopes of competitors

- Two product families: PolyPEPI "Off-the-shelf" and PEPI-Panel "Rapidly formulated fully personalized" therapeutic peptide treatments; produced through commercially scalable, highly cost effective processes, without need for tumor biopsy

- First-in-class predictive biomarker candidate identified for the selection of likely responders (Companion Diagnostic using a buccal swab)

- We aim to establish PolyPEPI immunotherapy as the foundation of combination treatments, accessible to patients worldwide addressing virtually all solid tumors

- New funding round to enable first ever randomized test of an Off-The-Shelf Peptide Immunotherapy in Late-Stage MSS Colorectal Cancer Phase 2B trial (n=140) led by Charite Berlin with support from Junshi Biosciences

Alphyn is developing a pipeline of Multi-Target Therapeutics® for dermatology based on its unique Zabalafin Drug Platform. The Platform is an impactful innovation because it has multiple bioactive compounds with multiple mechanisms of action to treat individual diseases in multiple ways, be more efficacious, and and treat multiple diseases. Importantly, drugs from our platform have strong safety, side effect, and patient tolerability profiles.

The company’s lead candidate, Zabalafin Hyrdogel (ZH), is completing Phase 2b trials to address the $41B opportunity in atopic dermatitis (AD). Results are expected Q2-2026. Based on Phase 2a results and interim blinded results, Alphyn believes ZH is uniquely positioned to be the first drug to directly target AD’s four key and interconnected problems – itch, inflammation, bacteria, and dry skin.

Alphyn’s second drug indication for ZH treats molluscum contagiosum virus (MCV), uniquely directly targeting the disease’s multiple problems that include for the first time directly killing the virus itself, itch, inflammation and, in certain patients, dermatitis and bacterial infection with its associated pain. It is currently nearing close of enrollment in the Phase 2 clinical trial with results expected early Q3-2026.

Alphyn has a strong patent portfolio, with U.S. patent protection to 2043, and a notice of allowance from the European patent office expected to publish in the Q1-2026. Global applications for additional patents are underway. Alphyn’s market protection is enhanced with the addition of health authority compliant drug raw material supply sufficient to provide $4.8 Billion in sales.

Alphyn closed a $25 million, twice over-subscribed Series B financing in 2025, bringing the company’s total raised to more than $33 million since it became operational in 2020.

At Tarian Pharma, We Believe That Real Innovation Cares We envision a future where supportive care in oncology is proactive, science-driven, and patient-centered, enabling individuals to complete their cancer treatment with fewer dermatological side effects and improved survival and increased remission rates. Patients undergoing cancer treatment face more than the disease itself: they face a cascade of dermatological side effects that affect comfort, self-esteem, and the ability to complete treatment. We developed a one and only product: a topical shield designed to actively protect the skin, improve quality of life, and enhance adherence to cancer therapy. It’s not just a product. It’s the guardian of your skin — simple yet essential.

Ymmunobio is a preclinical-stage oncology company advancing a first-in-class ADC treatment solution based on the proprietary tumor specific antigen (TSA) NPTXR, a neo-expressed membrane protein found exclusively on cancer cells. The company’s lead asset, YB-811, an Antibody Drug Conjugate (ADC), is designed to selectively target NPTXR-positive tumors with no off-tumor toxicity risk, leveraging third-generation linker-payload chemistry for superior safety and efficacy. Ymmunobio’s tumor marker shows extraordinarily high prevalence (57–98%) in more than a dozen of the most common and lethal cancers, enabling unmatched market breadth. The company holds exclusive global IP and intends to complete human proof-of-concept by 2028.

SonoTarg is on track to change the landscape of cancer treatment with a suite of targeted, low toxicity therapies that treat both primary tumours and metastatic disease. SonoTarg is an oncology biotech spinout company from the Universities of Oxford and Ulster and is based in Northern Ireland. The company has developed a suite of ultrasound-responsive, microbubble-based therapeutics for treating solid tumours with targeted, low dose chemotherapy and sonodynamic therapy (SDT). SonoTarg’s approach has proved highly effective against different solid tumour types, without the adverse effects associated with conventional chemotherapy. The SDT component elicits a powerful, local cytotoxic effect and simultaneously engages the immune system, providing the potential to treat metastatic disease in addition to the target tumour. This ‘abscopal’ effect has been confirmed in vivo and furthermore, preclinical data shows that the efficacy of existing immune checkpoint inhibitors can be augmented when given in combination with the SonoTarg product. SonoTarg is now ready to execute a phase I clinical trial which will generate safety and proof of mechanism data in newly diagnosed, breast cancer patients. SonoTarg is seeking £3.8Mn to enable the completion of this trial by end of 2027.